Van ECK Associates Corp increased its position in shares of Oaktree Specialty Lending Co. (NASDAQ:OCSL – Free Report) by 7.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,022,801 shares of the credit services provider’s stock after buying an additional 137,508 shares during the period. Van ECK Associates Corp owned 2.46% of Oaktree Specialty Lending worth $32,567,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in OCSL. SG Americas Securities LLC bought a new stake in shares of Oaktree Specialty Lending during the 1st quarter worth about $624,000. Significant Wealth Partners LLC grew its position in shares of Oaktree Specialty Lending by 217.9% in the first quarter. Significant Wealth Partners LLC now owns 204,075 shares of the credit services provider’s stock valued at $4,012,000 after purchasing an additional 139,881 shares during the last quarter. Arnhold LLC increased its stake in shares of Oaktree Specialty Lending by 9.0% during the first quarter. Arnhold LLC now owns 36,406 shares of the credit services provider’s stock worth $716,000 after purchasing an additional 3,000 shares during the period. ProShare Advisors LLC acquired a new stake in Oaktree Specialty Lending during the 1st quarter worth approximately $210,000. Finally, Entropy Technologies LP boosted its stake in Oaktree Specialty Lending by 29.8% in the 1st quarter. Entropy Technologies LP now owns 35,427 shares of the credit services provider’s stock valued at $696,000 after purchasing an additional 8,137 shares during the period. 36.79% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on OCSL. StockNews.com cut shares of Oaktree Specialty Lending from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. B. Riley cut their price target on Oaktree Specialty Lending from $18.50 to $17.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. JPMorgan Chase & Co. lowered their price objective on Oaktree Specialty Lending from $20.00 to $18.50 and set an “overweight” rating on the stock in a research note on Monday, July 29th. Keefe, Bruyette & Woods upgraded Oaktree Specialty Lending to a “hold” rating in a research report on Friday, August 2nd. Finally, Oppenheimer cut Oaktree Specialty Lending from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $20.00 to $18.00 in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Oaktree Specialty Lending has a consensus rating of “Hold” and a consensus target price of $18.00.
Oaktree Specialty Lending Price Performance
OCSL stock opened at $15.59 on Tuesday. Oaktree Specialty Lending Co. has a 1 year low of $15.56 and a 1 year high of $21.64. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.17 and a quick ratio of 0.17. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 17.92 and a beta of 1.09. The company has a 50 day simple moving average of $16.42 and a 200 day simple moving average of $17.81.
About Oaktree Specialty Lending
Oaktree Specialty Lending Corporation is a business development company. The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies.
Featured Articles
- Five stocks we like better than Oaktree Specialty Lending
- Using the MarketBeat Stock Split Calculator
- Intel: Is Now the Time to Be Brave?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Are Growth Stocks and Investing in Them
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Oaktree Specialty Lending Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oaktree Specialty Lending and related companies with MarketBeat.com's FREE daily email newsletter.